The pharmaceutical industry is ready to fall off a cliff — a “patent cliff.” Over the next few years, some of the world’s most popular and lucrative medicines will go off patent, and generic competition will siphon an estimate…
Here’s a roundup of some of Wednesday’s major pharmaceutical news: An FDA panel gave Human Genome Sciences a boost with a thumbs-up for its lupus drug, Benlysta; Merck’s experimental heart drug appears to work well without side…
Swiss pharmaceutical company Novartis announced Tuesday that it had discontinued the development of two drugs — the hepatitis C treatment Zalbin, and antifungal agent Mycograb. The company will take impairment charges of appro…
French pharmaceutical company Sanofi-Aventis announced a 10-year agreement with Covance on Thursday under which the Princeton, N.J.-based contract research firm will provide it with drug development services. Sanofi-Aventis wi…